Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Grancini is active.

Publication


Featured researches published by Anna Grancini.


Journal of Clinical Microbiology | 2012

Cross-Reactivity of Fusarium spp. in the Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay

Anna Maria Tortorano; Maria Carmela Esposto; Anna Prigitano; Anna Grancini; C. Ossi; Caterina Cavanna; Giuliana Lo Cascio

ABSTRACT Nine of 11 hematological patients with disseminated/deep-seated Fusarium infection tested at least twice for Aspergillus galactomannan (GM) had repeated positive results in the absence of Aspergillus isolation in culture. The centrifuged supernatants of 12 Fusarium isolates were tested by a GM enzyme-linked immunosorbent assay (EIA). All the isolates produced positive reactions when tested undiluted. These results show cross-reactivity of Fusarium spp. with Aspergillus GM that may constitute a drawback with respect to the specificity of the Platelia EIA.


Mycoses | 2012

INVASIVE FUNGAL INFECTIONS IN THE INTENSIVE CARE UNIT: A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL STUDY IN ITALY (2006-2008)

Anna Maria Tortorano; Giovanna Dho; Anna Prigitano; Giuseppe Breda; Anna Grancini; Vincenzo Emmi; Caterina Cavanna; Giovanni Marino; Silvia Morero; C. Ossi; Giacomo Delvecchio; M. Passera; Vitaliano Cusumano; Antonio David; Giuseppina Bonaccorso; Alberto Corona; Myriam Favaro; Chiara Vismara; Maria Graziella Garau; Susanna Falchi; M. Tejada

Critically ill patients admitted to intensive care units (ICU) are highly susceptible to healthcare‐associated infections caused by fungi. A prospective sequential survey of invasive fungal infections was conducted from May 2006 to April 2008 in 38 ICUs of 27 Italian hospitals. A total of 384 fungal infections (318 invasive Candida infections, three cryptococcosis and 63 mould infections) were notified. The median rate of candidaemia was 10.08 per 1000 admissions. In 15% of cases, the infection was already present at the time of admission to ICU. Seventy‐seven percent of Candida infections were diagnosed in surgical patients. Candida albicans was isolated in 60% of cases, Candida glabrata and Candida parapsilosis in 13%, each. Candida glabrata had the highest crude mortality rate (60%). Aspergillus infection was diagnosed in 32 medical and 25 surgical patients. The median rate was 6.31 per 1000 admissions. Corticosteroid treatment was the major host factor. Aspergillosis was demonstrated to be more severe than candidiasis as the crude mortality rate was significantly higher (63% vs. 46%), given an equal index of severity, Simplified Acute Physiology Score (SAPS‐II). The present large nationwide survey points out the considerable morbidity and mortality of invasive fungal infections in surgical as well as medical patients in ICU.


Antimicrobial Agents and Chemotherapy | 2008

Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy

Anna Maria Tortorano; Anna Prigitano; Giovanna Dho; Maria Carmela Esposto; Claudia Gianni; Anna Grancini; C. Ossi; Maria Anna Viviani

ABSTRACT Fusarium isolates from 75 Italian patients were identified by molecular methods, and their susceptibilities to antifungals were tested in vitro. Fusarium verticillioides was the species most frequently isolated from deep-seated infections, and F. solani was the species most frequently isolated from superficial infections. F. solani isolates showed high azole MICs, while F. verticillioides isolates showed low posaconazole MICs.


Journal of Medical Microbiology | 2012

Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units

Anna Maria Tortorano; Anna Prigitano; Giovanna Dho; Anna Grancini; M. Passera

The antifungal susceptibility pattern of 302 Candida isolates collected during an Italian survey on invasive fungal infections in an intensive care setting was investigated. The results were correlated with some epidemiological data and compared with the antifungal profiles obtained in a previous survey. No resistance to echinocandins was detected. The overall resistance levels to fluconazole, posaconazole and voriconazole were 12.6, 6.0 and 7.1 %, respectively. Candida tropicalis and Candida parapsilosis accounted for more than half of all the fluconazole resistant isolates. Reduced susceptibility to fluconazole is not uncommon among isolates (12.3 %) and appears to be increasing, particularly among C. parapsilosis isolates, which showed an increase in resistant isolates from 2 % in the 1990s to 25.8 % in the present study. Routine antifungal susceptibility testing of this species is therefore recommended.


European Journal of Clinical Microbiology & Infectious Diseases | 2000

Is a Kit for Identification of Clinical Yeasts Correctly Evaluated When Released onto the Market

Anna Maria Tortorano; F. Barchiesi; Manso E; Maria Teresa Montagna; C. Farina; L. Ferrari; A. Raballo; Anna Grancini; Gianluigi Lombardi

E. coli 0.016 0.25 4.0 synergistic synergistic (0.004/0.125) (0.004/2.0) K. pneumoniae 0.03 0.5 16.0 additive additive K. oxytoca 0.03 0.125 8.0 synergistic synergistic (0.016/0.03) (0.016/4.0) E. cloacae 0.03 4.0 16.0 additive additive E. aerogenes 0.03 0.5 32.0 synergistic additive (0.008/0.125) S. marcescens 0.25 0.5 16.0 synergistic synergistic (0.125/0.125) (0.125/8.0) C. freundii 0.03 1.0 128.0 synergistic synergistic (0.008/0.5) (0.008/32.0) P. mirabilis 0.25 32.0 4.0 synergistic additive (0.125/8.0)


Medical Mycology | 2018

Epidemiological trends of cryptococcosis in Italy: Molecular typing and susceptibility pattern of Cryptococcus neoformans isolates collected during a 20-year period

Massimo Cogliati; Anna Prigitano; Maria Carmela Esposto; Luisa Romanò; Anna Grancini; Alberto Zani; Anna Maria Tortorano

Abstract In the present study clinical data and isolates from cases of cryptococcosis recorded during clinical surveys carried out in Italy from 1997 to 2016, were investigated. Molecular typing and antifungal susceptibility testing were performed in order to delineate the epidemiological trend of cryptococcosis in Italy and to define wild‐type population for four different antifungal compounds. During the studied period, a total of 302 cases collected from 32 centers of 11 Italian regions were recorded. Analysis of clinical data showed a significant increase of frequency (from 7% to 38%) of cryptococcosis in human immunodeficiency virus (HIV)‐negative patients primarily with hematologic malignancies and solid organ transplantations. The prevalence of the molecular types has significantly changed during the study period, showing an increase of VNIII isolates from 11% to 41% in HIV‐negative patients, and a decrease of VNIV isolates from 36% to 16%. Antifungal susceptibility testing allowed us to calculate the epidemiological cut‐off for flucytosine (1 mg/l), fluconazole (8 mg/l), itraconazole (0.5 mg/l), and voriconazole (0.25 mg/l). Most of the isolates were wild‐type strains. Comparison of the MIC distributions according to molecular types showed that VNIV isolates had lower MICs for fluconazole and itraconazole than the VNI and VIII isolates. The current study emphasizes that the epidemiology of cryptococcosis in Italy has significantly changed over the last decades.


Travel Medicine and Infectious Disease | 2013

A case of Histoplasma capsulatum endophthalmitis diagnosed in Italy

Anna Grancini; Manuela Colosimo; Chiara Mapelli; Massimo Cogliati; Francesco Pallotti; Romualdo Grande; Erminio Torresani; Anna Maria Tortorano

Histoplasma capsulatum var. capsulatum is a dimorphic fungus endemic in the eastern United States and most countries of Latin America. Sporadic cases of histoplasmosis have been reported in Europe, mainly in immigrants or people returning from highly endemic areas. We report a case of 64-year-old Italian man with endophthalmitis, an unusual presentation of H. capsulatum infection. The patient shows redness, blurred vision, localized pain in the right eye. H. capsulatum was cultured from a vitreous biopsy and yeast forms were seen at histology.


The New England Journal of Medicine | 2017

Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

Emanuela Orsi; Anna Grancini

BACKGROUND Degludec is an ultralong‐acting, once‐daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open‐label studies have shown lower day‐to‐day variability in the glucose‐lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double‐blind, treat‐to‐target, event‐driven cardiovascular outcomes trial. The primary composite outcome in the time‐to‐event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity‐adjusted secondary outcome. RESULTS Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (±SD) glycated hemoglobin level was 8.4±1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5±1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128±56 vs. 136±57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups. CONCLUSIONS Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events. (Funded by Novo Nordisk and others; DEVOTE ClinicalTrials.gov number, NCT01959529.)


Case reports in infectious diseases | 2016

Mycoplasma hominis Induces Mediastinitis after a Tonsillar Abscess.

Anna Grancini; Manuela Colosimo; Antonella Restelli; Rosaria Colombo; Anna Maraschini; Cristina Pozzi; Giuseppe Breda; Alessandro Protti; Milena Arghittu; Luca Gallelli; Rita Maiavacca

Mycoplasma hominis is commonly involved in genitourinary tract infections. We report a 59-year-old man who developed a M. hominis-associated mediastinitis following acute tonsillar infection.


Microbiologia Medica | 2011

Shigella flexneri-induced vaginitis in a prepubertal children: description of a case

Antonella Restelli; Manuela Colosimo; Anna Maraschini; Anna Grancini; Rosaria Colombo; Romualdo Grande; Maria Rosa Araldi; Erminio Torresani

In prepuberal girls vulvo-vaginitis are caused by germs of intestinal origin,mycetes, Gardnerella vaginalis, protozoa. Shigella is an uncommon agent able to induce valvovaginitis in children. We report the case of a 7-year-old girl with chronic vulvo-vaginitis caused by S. flexneri. Antibiotic Susceptibility Testing revealed that S. flexnery was sensible to cefotaxime, amoxicillin, imipenem, ciprofloxacin, but resistant to amikacin, cefazolin, gentamycin, ampicillin and tetracycline. A treatment with ciprofloxacin brought to a rapid resolution of all symptoms. At the follows up at 3 and 6 months the patient did not report symptoms of infection or articular cartilage abnormality; microbiological evaluations were also negative. Even if it is a single case report and other clinical trial may be performed in order to validate this hypothesis,we speculate that in patient with vulvo-vaginal infection living in environment with low hygiene care, a carefully microbiological evaluation of uncommon agents may be performed.

Collaboration


Dive into the Anna Grancini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Ossi

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Manuela Colosimo

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar

Romualdo Grande

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonella Restelli

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar

Erminio Torresani

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Researchain Logo
Decentralizing Knowledge